Business UpdateJun 1, 2026, 08:01 AM
Elicio Therapeutics Publishes Novel AMP-DNA Adjuvant Data in Science Advances
AI Summary
Elicio Therapeutics announced the publication of a peer-reviewed manuscript in Science Advances, detailing novel lymph node-targeting AMP-DNA adjuvant candidates. The preclinical data highlights the platform's ability to drive robust, durable immune responses through targeted delivery and activation of innate immune pathways, expanding beyond their initial clinical programs. This work reinforces the versatility of Elicio's AMP platform for developing next-generation immunotherapies across oncology and infectious disease.
Key Highlights
- Preclinical AMP-DNA adjuvants outperformed benchmark adjuvants, inducing more robust cellular immunity.
- AMP-DNA elicited high frequencies of antigen-specific, polyfunctional CD8+ and CD4+ T cell responses.
- Durable immune memory was observed for at least nine months, with rapid recall responses.
- Findings were replicated in non-human primates, showing strong cellular and humoral immune responses.
- Immune activation is driven through TBK1/IFN-I signaling pathways, a differentiated mechanism from AMP-CpG.
- The AMP platform is designed to enhance immune responses by directing therapeutics to lymph nodes.
Price Impact
More from ELTX